Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is a clinical-stage biopharmaceutical company with a strong pipeline and differentiated therapeutic platforms. While competition in the HER2-targeted therapy market is a concern, potential approvals of zanidatamab and other pipeline assets could lead to significant revenue growth. However, regulatory risks must be considered as delays or failures to gain approval could impact the company's valuation.

Bears say

Zymeworks is facing regulatory and clinical risks as it advances its pipeline, with potential catalysts including December 2026 US Phase 1 approval of zanidatamab for GEA and future interim OS findings, potential partner JAZZ's global Ziihera approval in August 2026, ZW209's IND submission in mid-2026, and recent data being encouraging. Also, a sum-of-the-parts based DCF yields a $3.28B total firm value, with a $58 price target and various positive catalysts and competitive risks affecting the expected value.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.